Form 4: Corcept Therapeutics Director James N. Wilson Reports Gift of Shares
SEC Form 4 Filing
Director James N. Wilson reported a gift of 2,000 common stock shares and disclaims beneficial ownership except for pecuniary interest.
Summary
- On May 23, 2024, James N. Wilson, a director of Corcept Therapeutics, reported a transaction involving the company's common stock.
- Wilson gifted 2,000 shares of common stock.
- Following the transaction, Wilson indirectly owns 1,314,026 shares through the James N. Wilson and Pamela D. Wilson Trust and 901,067 shares through James and Pamela Wilson Family Partners.
- Wilson disclaims beneficial ownership of these shares except to the extent of his pecuniary interest.
Sentiment
Score: 5
Explanation: The document is a neutral regulatory filing detailing a transaction. It doesn't inherently convey positive or negative sentiment.
Industry Context
This filing is a routine disclosure of insider transactions, which are common in publicly traded companies. It provides transparency into the actions of company insiders.
Stakeholder Impact
- The transaction itself is unlikely to have a significant impact on stakeholders, but the disclosure provides transparency to shareholders.
Key Dates
| Date | Description |
|---|---|
| 05/23/2024 | Date of transaction: gift of 2,000 shares of common stock. |
| 05/28/2024 | Date of signature for the Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.